UNSPSC 51314345: Chlorpheniramine/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314345 Chlorpheniramine/phenylephrine is a Commodity code covering specific antihistamine and decongestant pharmaceutical products. State and local governments procure these medications primarily through multistate cooperative purchasing alliances, county health departments, and state pharmacy benefit programs serving public employees, health plans, and community health initiatives. The recent solicitations under this code reflect a broader pattern of state and local acquisition of generic pharmaceuticals and OTC products through centralized procurement mechanisms that establish contracts with manufacturers, which are then distributed to authorized wholesale partners and ultimately dispensed through government-supported health facilities and programs.

Recent activity spans three distinct issuing bodies and procurement models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 — this procurement establishes statewide and multistate contracts with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) for distribution across participating government facilities, with pricing weighted 75 percent on competitiveness and manufacturing compliance with cGMP and the Drug Supply Chain Security Act. Seminole County, Florida, issued IFB 60459723LAS on June 30, 2026, for naloxone and safe drug deactivation systems (1,900 units of naloxone and 800 systems annually) with a response deadline of July 26, 2023, directed to its Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, exploring direct-to-manufacturer prescription delivery models to inform future procurement strategy. Geographic activity centers on Texas, Florida, and the Upper Midwest (Minnesota and Oregon), with cooperative purchasing structures extending potential reach across multiple jurisdictions.